Sign In
Buy KNBWY
$16.48
+0.270 (+1.67%)
At Close: Jun 03, 2026
Kyowa Kirin Announces Abstract Presentation at the European Academy of Dermatology and Venereology (EADV) Congress
08:00am, Tuesday, 29'th Jul 2025
PRINCETON, N.J. and TOKYO , July 29, 2025 /PRNewswire/ -- Kyowa Kirin Co., Ltd.
– Encouraging clinical activity with deep responses demonstrated in the KOMET-007 trial with the combination of 600 mg ziftomenib with 7+3 in newly diagnosed patients with NPM1-m and KMT2A-r AML �
Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting
06:00pm, Monday, 02'nd Jun 2025
– CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R NPM1-m AML patients – – Consistent efficacy with comparable CR/CRh rates and clinically meaningful MRD-negative responses across pre-specified
– New Drug Application based on positive results from the Phase 2 KOMET-001 trial – – FDA assigns a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2025 – – Potenti
Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting
05:30pm, Thursday, 22'nd May 2025
– Results from KOMET-001 registration-directed trial of ziftomenib in R/R NPM1-m AML patients selected for oral presentation on Monday, June 2nd –
Kirin Holdings: Q1 Performance Had Mixed Takeaways
12:57pm, Wednesday, 21'st May 2025
I remain Neutral on Kirin Holdings, as both positives and negatives emerged from the latest quarterly results. 1Q25 operating income grew by a reasonably strong 10%, but this was helped by non-recurri
– Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r AML patients selected for oral presentation on Thursday, June 12th –
Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA
07:30am, Tuesday, 08'th Apr 2025
– Submission seeks approval for the treatment of adult patients with relapsed or refractory AML with a NPM1 mutation – – Submission seeks approval for the treatment of adult patients with relaps
KNBWY vs. BUD: Which Stock Is the Better Value Option?
12:46pm, Friday, 28'th Feb 2025
Investors with an interest in Beverages - Alcohol stocks have likely encountered both Kirin Holdings Co. (KNBWY) and Anheuser-Busch Inbev (BUD). But which of these two stocks is more attractive to val
Are Investors Undervaluing Kirin (KNBWY) Right Now?
10:46am, Friday, 28'th Feb 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Kyowa Kirin Announces Late-Breaking Abstract Presentation at the American Academy of Dermatology Annual Meeting 2025
08:00am, Wednesday, 26'th Feb 2025
PRINCETON, N.J. , Feb. 26, 2025 /PRNewswire/ -- Kyowa Kirin Co., Ltd.
KNBWY or BUD: Which Is the Better Value Stock Right Now?
12:41pm, Wednesday, 12'th Feb 2025
Investors with an interest in Beverages - Alcohol stocks have likely encountered both Kirin Holdings Co. (KNBWY) and Anheuser-Busch Inbev (BUD). But which of these two stocks is more attractive to val
Is Kirin (KNBWY) Stock Undervalued Right Now?
10:46am, Wednesday, 12'th Feb 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
– KOMET-001 registrational trial in R/R NPM1-m AML achieved primary CR/CRh endpoint; topline data submitted for presentation at an upcoming medical meeting –
TOKYO--(BUSINESS WIRE)--Kirin Holdings Company, Ltd. (Kirin Holdings) (TOKYO: 2503) and Kirin Beverage Company, Ltd. (Kirin Beverage) have been working with the Rainforest Alliance since October 2023
